Oradin Plus10 mg+240 mg

Oradin Plus is a fixed-dose combination of a non-sedating second-generation antihistamine (loratadine) and an oral decongestant (pseudoephedrine). It is indicated for:

• Established/FDA-approved use: Temporary relief of symptoms associated with seasonal and perennial allergic rhinitis (hay fever) and other upper respiratory allergies, including sneezing, rhinorrhea (runny nose), nasal congestion, and itchy/watery eyes, in patients who require both antihistamine and decongestant effects.
• Established/FDA-approved use: Temporary relief of nasal and sinus congestion associated with the common cold.
• Adjunct use: Relief of sinus pressure/discomfort associated with allergic rhinitis when accompanied by nasal congestion.

Oradin Plus is intended only for patients who have both allergy symptoms and nasal/sinus congestion; if congestion is not present, a decongestant component is not needed and loratadine alone may be more appropriate.

Loratadine + Pseudoephedrine extended-release tablets are available in the following commonly marketed strengths:

• Loratadine 5 mg + Pseudoephedrine sulfate 120 mg (taken twice daily)
• Loratadine 10 mg + Pseudoephedrine sulfate 240 mg (taken once daily)

Each tablet also contains standard inactive excipients used in extended-release tablet formulations.

Oradin Plus combines two active ingredients that act on different aspects of allergic and cold-related upper respiratory symptoms:

• Loratadine is a long-acting, non-sedating (second-generation) tricyclic antihistamine with selective peripheral H1-receptor antagonist activity.
• Pseudoephedrine is a sympathomimetic amine that acts as an oral nasal decongestant.

Together, Oradin Plus provides relief from both the histamine-mediated symptoms of allergy (sneezing, itching, rhinorrhea) and the vascular congestion component (stuffy nose, sinus pressure) of allergic rhinitis and the common cold. It is formulated as an extended-release tablet to allow once- or twice-daily dosing.

Oradin Plus belongs to the therapeutic class of antihistamine-decongestant combinations, used in the management of allergic rhinitis and upper respiratory allergy symptoms with nasal congestion.

Loratadine

Loratadine is a selective, peripherally-acting H1-receptor antagonist. It has minimal ability to cross the blood-brain barrier at therapeutic doses, which accounts for its low sedative potential compared with first-generation antihistamines. It blocks the effects of histamine released during allergic reactions, reducing sneezing, itching, and rhinorrhea. Loratadine is extensively metabolized in the liver (primarily via CYP3A4 and CYP2D6) to its active metabolite, desloratadine, and has an elimination half-life of approximately 8 hours (loratadine) and 28 hours (desloratadine).

Pseudoephedrine

Pseudoephedrine is an indirect-acting sympathomimetic amine that stimulates alpha-adrenergic receptors in the respiratory mucosa, producing vasoconstriction of the dilated nasal mucosal blood vessels. This reduces nasal tissue swelling/edema and mucosal hyperemia, relieving nasal and sinus congestion. It is largely excreted unchanged in the urine, with a half-life of roughly 5-8 hours (shorter in acidic urine).

In Loratadine + Pseudoephedrine, the two components act complementarily: loratadine addresses histamine-driven allergic symptoms while pseudoephedrine addresses vasomotor nasal congestion.

Oradin Plus tablets should be swallowed whole with a full glass of water, without regard to meals. Do not crush, chew, split, or dissolve the tablet, as this is an extended-release formulation.

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, is contraindicated with Oradin Plus due to the risk of a hypertensive crisis from the pseudoephedrine component (see Contraindications).
• Other sympathomimetics (e.g., other decongestants, appetite suppressants, certain stimulants): Concurrent use with Oradin Plus may have additive cardiovascular effects (increased blood pressure, heart rate); avoid combining unless directed by a physician.
• Antihypertensive agents (e.g., beta-blockers, methyldopa): Pseudoephedrine in Oradin Plus may reduce the antihypertensive effect of these medicines.
• CYP3A4/CYP2D6 inhibitors (e.g., ketoconazole, erythromycin, cimetidine): May increase plasma levels of loratadine when co-administered with Oradin Plus; clinically significant adverse effects are uncommon but caution is advised.
• CNS depressants and alcohol: Although loratadine is non-sedating at recommended doses, combined use with alcohol or other CNS depressants alongside Oradin Plus should be approached cautiously.

Side effects of Oradin Plus reflect the combined pharmacology of loratadine and pseudoephedrine.

Common

• Dry mouth
• Insomnia/difficulty sleeping
• Headache
• Nervousness or restlessness
• Dizziness
• Somnolence (less common than with sedating antihistamines)
• Fatigue
• Nausea
• Pharyngitis (sore throat)
• Decreased appetite

Less Common / Serious

• Palpitations, tachycardia, or increased blood pressure (related to the pseudoephedrine component)
• Urinary retention or difficulty urinating
• Allergic reactions, including rash, urticaria, or (rarely) anaphylaxis

Patients should seek medical attention promptly if signs of a serious allergic reaction, chest pain, marked increase in blood pressure, or irregular heartbeat occur while taking Oradin Plus.

Pregnancy: Data on Oradin Plus use during pregnancy are limited, particularly for the pseudoephedrine component, which has been associated in some studies with a small increased risk of specific birth defects (e.g., gastroschisis) when used in early pregnancy, though findings are not conclusive. Oradin Plus should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only after consulting a physician.

Lactation: Both loratadine and pseudoephedrine pass into breast milk. Pseudoephedrine may also reduce milk production/supply in breastfeeding mothers. Oradin Plus should be used during breastfeeding only if clearly needed, and a physician should be consulted before use.

• Use Oradin Plus with caution in patients with hypertension or cardiovascular disease, as the pseudoephedrine component can raise blood pressure and heart rate.
• Use with caution in patients with hyperthyroidism, diabetes mellitus, or increased intraocular pressure.
• Use with caution in men with benign prostatic hyperplasia (BPH) or bladder-neck obstruction, as pseudoephedrine's sympathomimetic effects may worsen urinary retention.
• Use with caution in patients with hepatic or renal impairment; dose adjustment may be required for the loratadine component (see Use in Special Populations).
• Discontinue Oradin Plus and consult a physician if symptoms do not improve within 7 days, if fever develops, or if nervousness, dizziness, or sleeplessness occurs.
• In several countries, including Bangladesh, pseudoephedrine-containing products such as Oradin Plus are subject to pharmacy dispensing restrictions/quantity limits because of the potential for diversion toward illicit stimulant manufacture; obtain this medicine only through legitimate pharmacy channels.
• Avoid driving or operating heavy machinery until you know how Oradin Plus affects you, as dizziness or drowsiness can occasionally occur.

Overdose of Oradin Plus may present with symptoms related to either component, such as marked drowsiness or, conversely, central nervous system stimulation (nervousness, tremor, insomnia, restlessness), rapid or irregular heartbeat, significantly elevated blood pressure, hallucinations, seizures, or headache. In severe cases, cardiovascular collapse can occur.

If an overdose of Oradin Plus is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to treat an overdose at home; take the medicine container with you if going to a hospital.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Elderly patients, particularly those with cardiovascular disease, prostatic hypertrophy, or renal impairment, should use Oradin Plus with caution due to increased sensitivity to the sympathomimetic effects of pseudoephedrine.

Hepatic Impairment

Patients with significant liver disease may have reduced clearance of loratadine; a lower dose or less frequent dosing of Oradin Plus may be advised by the physician.

Renal Impairment

In patients with a creatinine clearance below approximately 30 mL/min, clearance of both loratadine and pseudoephedrine is reduced; dose reduction or an extended dosing interval for Oradin Plus is generally recommended under physician supervision.

Pediatric Patients

Safety and efficacy of Oradin Plus extended-release tablets have not been established in children under 12 years of age; consult a physician for appropriate pediatric allergy and decongestant treatment.

Oradin Plus is generally intended for short-term, symptomatic use. If symptoms persist beyond 7 days, worsen, or are accompanied by fever, use should be stopped and a physician consulted, as continued self-treatment beyond this period is not recommended without medical supervision.

Loratadine + Pseudoephedrine is classified as a second-generation antihistamine and sympathomimetic oral decongestant combination product.

Loratadine + Pseudoephedrine works through two complementary mechanisms: loratadine selectively blocks peripheral histamine H1-receptors to reduce sneezing, itching, and rhinorrhea, while pseudoephedrine stimulates alpha-adrenergic receptors in nasal blood vessels to cause vasoconstriction, reducing nasal mucosal swelling and relieving congestion.

Oradin Plus extended-release tablets are not established as safe and effective for use in children under 12 years of age. Use in this age group is generally not recommended without specific physician guidance, and alternative pediatric-appropriate allergy treatments should be considered instead.